🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Aarti Drugs Limited AARTIDRUGS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.aartidrugs.co.in

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

READ MORE ›
₹380.40
-19.16% 1Y

Market & Price

Market Cap
₹3,471.91 Cr
Current Price
₹380.40
High / Low (52W)
₹542.14 / ₹319.75
Beta
0.36

Valuation

Stock P/E
17.79
Industry PE
37.60
Forward P/E
14.41
PEG Ratio
-
Book Value
₹169.79
Price to Book
2.24
P/S
1.35
EV/EBITDA
12.91
Dividend Yield
0.53%

Profitability & Returns

ROCE
12.92%
ROE
13.36%
ROA
5.67%
Profit Margin
7.60%
Op Margin
10.90%
EPS (Latest Qtr)
₹6.05
EPS (TTM)
₹21.38

Balance Sheet & Liquidity

Debt/Equity
0.37
Quick Ratio
0.93
Current Ratio
1.59
Debt
₹576.64 Cr
Total Assets
₹2,815.26 Cr
Current Assets
₹1,467.77 Cr
Working Capital
₹545.51 Cr

Ownership

Promoter Holding
60.16%
Chg in Prom Hold
-
FII / Inst Holding
11.14%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹4,022.85 Cr
Total Revenue (TTM)
₹2,565.31 Cr
EBITDA
₹311.59 Cr
Free Cash Flow
₹-6.01 Cr
Operating Cash Flow
₹253.54 Cr
Shares Outstanding
₹9.13 Cr
Gross Margin
36.90%
Payout Ratio
9.36%

Growth (CAGR)

Revenue 5Y
-1.76%
Profit 5Y
5.43%
Revenue (YoY)
6.40%
Earnings (YoY)
-12.00%

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -1.8% CAGR over 5 years.
  • Trading 29.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AARTIDRUGS Aarti Drugs Limited NSEPHARMA 380.40 17.79 ₹3,471.91 Cr 0.53% 12.92% 13.36% -1.76% 5.43%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -556.60 Cr676.76 Cr590.51 Cr652.79 Cr601.71 Cr720.30 Cr
Cost of Revenue -350.29 Cr435.55 Cr373.39 Cr408.29 Cr386.64 Cr450.42 Cr
Gross Profit -206.31 Cr241.21 Cr217.12 Cr244.50 Cr215.07 Cr269.88 Cr
Operating Expenses -158.38 Cr162.78 Cr157.76 Cr176.47 Cr177.98 Cr192.12 Cr
Operating Income -47.93 Cr78.43 Cr59.36 Cr68.03 Cr37.09 Cr77.76 Cr
EBITDA -73.63 Cr95.19 Cr74.39 Cr84.37 Cr56.26 Cr96.56 Cr
Interest Expense -9.07 Cr9.16 Cr8.56 Cr7.70 Cr9.29 Cr8.16 Cr
Pretax Income -50.76 Cr71.15 Cr51.11 Cr60.41 Cr29.02 Cr70.36 Cr
Tax Provision -13.67 Cr8.38 Cr-2.86 Cr15.25 Cr-11.53 Cr15.10 Cr
Net Income -37.05 Cr62.86 Cr53.91 Cr45.28 Cr40.54 Cr55.19 Cr
Diluted EPS 3.834.066.885.914.954.446.05

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -2,705.57 Cr2,508.87 Cr2,387.03 Cr2,565.31 Cr
Cost of Revenue -2,222.60 Cr2,024.01 Cr1,542.10 Cr1,618.72 Cr
Gross Profit -482.97 Cr484.87 Cr844.93 Cr946.59 Cr
Operating Expenses -216.62 Cr207.16 Cr613.65 Cr704.36 Cr
Operating Income -266.35 Cr277.70 Cr231.28 Cr242.23 Cr
EBITDA -307.80 Cr320.49 Cr303.42 Cr311.58 Cr
Interest Expense -33.29 Cr33.52 Cr35.87 Cr33.71 Cr
Pretax Income -224.18 Cr235.53 Cr211.77 Cr210.90 Cr
Tax Provision -57.82 Cr63.94 Cr43.67 Cr15.96 Cr
Net Income -166.31 Cr171.42 Cr168.16 Cr194.92 Cr
Diluted EPS 22.1417.9718.5618.35-

Compounded Sales Growth

5 Years:-1.76%
1 Year:6.40%

Compounded Profit Growth

5 Years:5.43%
1 Year:-12.00%

Stock Price Performance

1 Year:-19.16%
6 Months:-10.69%
3 Months:+2.95%
1 Month:+1.09%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -2,421.40 Cr2,432.36 Cr2,574.68 Cr2,815.26 Cr
Current Assets -1,491.79 Cr1,320.72 Cr1,338.36 Cr1,467.77 Cr
Cash & Equivalents -7.50 Cr6.74 Cr4.58 Cr7.27 Cr
Inventory -516.29 Cr485.89 Cr472.93 Cr490.78 Cr
Receivables -864.84 Cr704.55 Cr751.18 Cr829.87 Cr
Total Liabilities -1,228.73 Cr1,150.40 Cr1,205.34 Cr1,266.04 Cr
Current Liabilities -949.48 Cr795.54 Cr836.97 Cr922.26 Cr
Long Term Debt -204.68 Cr275.33 Cr284.00 Cr256.87 Cr
Total Debt -608.91 Cr564.28 Cr615.07 Cr576.64 Cr
Total Equity -1,192.43 Cr1,281.55 Cr1,369.00 Cr1,548.86 Cr
Shares Outstanding -9.26 Cr9.19 Cr9.13 Cr9.13 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -133.32 Cr358.92 Cr244.58 Cr253.54 Cr
Investing Cash Flow --163.97 Cr-223.65 Cr-164.63 Cr-173.41 Cr
Financing Cash Flow -16.54 Cr-136.03 Cr-82.12 Cr-77.44 Cr
Capital Expenditure --164.82 Cr-226.33 Cr-177.16 Cr-173.32 Cr
Free Cash Flow --31.50 Cr132.59 Cr67.42 Cr80.22 Cr
Net Change in Cash --14.11 Cr-76.07 L-2.17 Cr2.69 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -17.9%19.3%35.4%36.9%
Operating Margin % -9.8%11.1%9.7%9.4%
Net Margin % -6.1%6.8%7.0%7.6%
ROE % -13.9%13.4%12.3%12.6%
ROCE % -18.1%17.0%13.3%12.8%

Shareholding Pattern

Insiders
60.16%
Institutions
11.14%
Public Float
27.97%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AARTIDRUGS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks